Home > PE Ratio > CONCORD BIOTECH

CONCORD BIOTECH
PE (Price/Earnings) Ratio

The Current P/E Ratio of CONCORD BIOTECH is 65.12.

Share Price ₹2,046.6Jan 29,2025
Market Cap ₹21,406.9 Cr
Earnings-TTM₹328.7 CrTTM-Consolidated Results
Price/Earnings65.12xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for CONCORD BIOTECH
Please provide your vote to see the results
CONCORD BIOTECH is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of CONCORD BIOTECH

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of CONCORD BIOTECH is calculated as :

Current Market Cap [ ₹21,406.9 Cr] as on Jan 29,2025

(/) Earnings [ ₹328.7 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 65.12x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for CONCORD BIOTECH , the investors are currently willing to pay 65.12 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD BIOTECH !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of CONCORD BIOTECH over the last five years.

Historical PE (Price/Earnings) ratio chart of CONCORD BIOTECH


PE Ratio Performance Analysis for CONCORD BIOTECH

- CONCORD BIOTECH 's latest p/e ratio is 65.12x.

- CONCORD BIOTECH 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 10.34x.

- CONCORD BIOTECH 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, CONCORD BIOTECH 's p/e ratio peaked in Mar2024 at 51.68x.

- CONCORD BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 0x.


How does CONCORD BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
CONCORD BIOTECH 328.7165.1221,406.9
SUN PHARMACEUTICAL INDUSTRIES LTD11,136.5037.42416,692.0
CIPLA LTD5,000.4323.00115,000.0
DR REDDYS LABORATORIES LTD5,428.6018.1798,616.4
ZYDUS LIFESCIENCES LTD4,298.9021.8393,841.4
DIVIS LABORATORIES LTD1,836.0081.27149,215.0
MANKIND PHARMA LTD2,050.7349.85102,232.0
TORRENT PHARMACEUTICALS LTD1,862.0061.06113,701.0
LUPIN LTD2,651.9435.5794,337.9
AUROBINDO PHARMA LTD3,598.8318.6767,192.9
ABBOTT INDIA LTD1,284.6642.1454,136.1

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD BIOTECH 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 18.17x
Max industry PE 81.27x
Median industry PE 37.42x
Average industry PE 41.28x



You may also like the below Video Courses